X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Blister pack with dollars instead of pills From 2011-2019, large drug companies had a return on investment capital of 17.3 percent, compared to the average ROIC across all other industries of 11.5 percent. (Photo: Shutterstock)

Pharma has been countering the call for government-mandated price restrictions by arguing that lower industry revenues would stymie development of needed drugs.

A group of researchers at the West Health Policy Center and Johns Hopkins Bloomberg School of Public Health say that’s a lot of hooey–claiming they have the data to back that up.

Katie Kuehner-Hebert

Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.

More from this author

 

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.